Terms: = Pancreatic cancer AND NFE2L2, ENSG00000116044, 4780, Q16236, NRF2 AND Treatment
67 results:
1. ACA-28, an ERK MAPK Signaling Modulator, Exerts Anticancer Activity through ROS Induction in Melanoma and pancreatic cancer Cells.
Takasaki T; Hamabe Y; Touchi K; Khandakar GI; Ueda T; Okada H; Sakai K; Nishio K; Tanabe G; Sugiura R
Oxid Med Cell Longev; 2024; 2024():7683793. PubMed ID: 38500550
[TBL] [Abstract] [Full Text] [Related]
2. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/nrf2 axis in pancreatic cancer.
Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
[TBL] [Abstract] [Full Text] [Related]
3. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract] [Full Text] [Related]
4. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in pancreatic cancer.
Kim MJ; Kim HS; Kang HW; Lee DE; Hong WC; Kim JH; Kim M; Cheong JH; Kim HJ; Park JS
Cells; 2023 Oct; 12(20):. PubMed ID: 37887353
[TBL] [Abstract] [Full Text] [Related]
5. Identification and validation of potential diagnostic signature and immune cell infiltration for NAFLD based on cuproptosis-related genes by bioinformatics analysis and machine learning.
Ouyang G; Wu Z; Liu Z; Pan G; Wang Y; Liu J; Guo J; Liu T; Huang G; Zeng Y; Wei Z; He S; Yuan G
Front Immunol; 2023; 14():1251750. PubMed ID: 37822923
[TBL] [Abstract] [Full Text] [Related]
6. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
7. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing nrf2 activity.
Ruan Q; Wen C; Jin G; Yuan Z; Yang X; Wen Z; Huang G; Li G; Deng J; Bai Y
Phytomedicine; 2023 Sep; 118():154990. PubMed ID: 37494874
[TBL] [Abstract] [Full Text] [Related]
8. Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells.
Wang Z; Li W; Wang X; Zhu Q; Liu L; Qiu S; Zou L; Liu K; Li G; Miao H; Yang Y; Jiang C; Liu Y; Shao R; Wang X; Liu Y
Chin Med J (Engl); 2023 Sep; 136(18):2210-2220. PubMed ID: 37488674
[TBL] [Abstract] [Full Text] [Related]
9. Mechanical Regulation of Redox Balance via the Induction of the PIN1/nrf2/ARE Axis in pancreatic cancer.
Liang C; Rong Z; Tuerhong A; Meng Q; Hua J; Liu J; Zhang B; Wang W; Yu X; Shi S; Xu J
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834887
[TBL] [Abstract] [Full Text] [Related]
10. Cinchonine-induced cell death in pancreatic cancer cells by downregulating RRP15.
Liang F; Lv Y; Qiao X; Zhang S; Shen S; Wang C; Xu G; Zou X; Wang L; Zhang B
Cell Biol Int; 2023 May; 47(5):907-919. PubMed ID: 36682038
[TBL] [Abstract] [Full Text] [Related]
11. Periplocin exerts antitumor activity by regulating nrf2-mediated signaling pathway in gemcitabine-resistant pancreatic cancer cells.
Bae ES; Byun WS; Ock CW; Kim WK; Park HJ; Lee SK
Biomed Pharmacother; 2023 Jan; 157():114039. PubMed ID: 36423542
[TBL] [Abstract] [Full Text] [Related]
12. UBR7 inhibits HCC tumorigenesis by targeting Keap1/nrf2/Bach1/HK2 and glycolysis.
Zhao L; Kang M; Liu X; Wang Z; Wang Y; Chen H; Liu W; Liu S; Li B; Li C; Chang A; Tang B
J Exp Clin Cancer Res; 2022 Nov; 41(1):330. PubMed ID: 36419136
[TBL] [Abstract] [Full Text] [Related]
13. Targeting mitochondrial dysfunctions in pancreatic cancer evokes new therapeutic opportunities.
Sarwar A; Zhu M; Su Q; Zhu Z; Yang T; Chen Y; Peng X; Zhang Y
Crit Rev Oncol Hematol; 2022 Dec; 180():103858. PubMed ID: 36257540
[TBL] [Abstract] [Full Text] [Related]
14. CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating nrf2 and the NF-κB signaling pathway.
Zhang Z; Chen L; Zhao C; Gong Q; Tang Z; Li H; Tao J
Cell Biol Toxicol; 2023 Aug; 39(4):1549-1560. PubMed ID: 35913601
[TBL] [Abstract] [Full Text] [Related]
15. Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer.
Yang PW; Xu PL; Cheng CS; Jiao JY; Wu Y; Dong S; Xie J; Zhu XY
J Ethnopharmacol; 2022 Oct; 297():115516. PubMed ID: 35817247
[TBL] [Abstract] [Full Text] [Related]
16. Photosensitization of pancreatic cancer cells by cationic alkyl-porphyrins in free form or engrafted into POPC liposomes: The relationship between delivery mode and mechanism of cell death.
Di Giorgio E; Ferino A; Choudhary H; Löffler PMG; D'Este F; Rapozzi V; Tikhomirov A; Shchekotikhin A; Vogel S; Xodo LE
J Photochem Photobiol B; 2022 Jun; 231():112449. PubMed ID: 35504235
[TBL] [Abstract] [Full Text] [Related]
17. Mitochondrial Calcium Uniporter Drives Metastasis and Confers a Targetable Cystine Dependency in pancreatic cancer.
Wang X; Li Y; Li Z; Lin S; Wang H; Sun J; Lan C; Wu L; Sun D; Huang C; Singh PK; Hempel N; Trebak M; DeNicola GM; Hao J; Yang S
Cancer Res; 2022 Jun; 82(12):2254-2268. PubMed ID: 35413105
[TBL] [Abstract] [Full Text] [Related]
18. CRISPR-Cas9-based genome-wide screening identified novel targets for treating sorafenib-resistant hepatocellular carcinoma: a cross-talk between FGF21 and the nrf2 pathway.
Chen J; Jiang S; Shao H; Li B; Ji T; Staiculescu D; He J; Zhao J; Cai L; Liang X; Xu J; Cai X
Sci China Life Sci; 2022 Oct; 65(10):1998-2016. PubMed ID: 35380342
[TBL] [Abstract] [Full Text] [Related]
19. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract] [Full Text] [Related]
20. Fatty acid binding protein 4 regulates pancreatic cancer cell proliferation via activation of nuclear factor E2-related factor 2.
Wirth K; Shinoda S; Sato-Dahlman M; Dickey DM; Bernlohr DA; Ikramuddin S; Yamamoto M
Surg Obes Relat Dis; 2022 Apr; 18(4):485-493. PubMed ID: 34998697
[TBL] [Abstract] [Full Text] [Related]
[Next]
